Ever since biosimilar competition to AbbVie Inc.'s Humira (adalimumab) began to hit the US market in early 2023, all eyes have been on the uptake of off-patent rivals, given that the product represented the largest loss-of-exclusivity opportunity in history – valued at roughly $17bn in terms of brand sales.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?